Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

DICERNA PHARMACEUTICALS, INC.

(DRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
CommuniquÚs de presse de la sociÚtÚ DICERNA PHARMACEUTICALS, INC.
11/22SHAREHOLDER ALERT : Monteverde & Associates PC Announces an Investigation of Dicerna Pharm..
PR
11/18SHAREHOLDER ALERT : WeissLaw LLP Investigates Dicerna Pharmaceuticals, Inc.
PR
11/18SHAREHOLDER ALERT : Ademi LLP investigates whether Dicerna Pharmaceuticals, Inc. has obtai..
PR
11/18DICERNA MERGER INVESTIGATION : Halper Sadeh LLP Announces Investigation Into Whether the S..
BU
11/18DICERNA PHARMACEUTICALS : Novo Nordisk to Acquire Dicerna - Form 8-K
PU
11/18DICERNA PHARMACEUTICALS INC : Entry into a Material Definitive Agreement, Other Events, Fi..
AQ
11/18Novo Nordisk to Acquire Dicerna
BU
11/12Dicerna Announces Two Targets Meet Preclinical Proof of Principle Criteria in Neurodege..
BU
11/12Dicerna Presents Data From Phase 1 Trial of Belcesiran at American Association for the ..
BU
11/09Dicerna Announces Third Quarter 2021 Financial Results and Provides a Business Update -..
PU
11/09DICERNA PHARMACEUTICALS INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIO..
AQ
11/09DICERNA PHARMACEUTICALS : Q3 Earnings Snapshot
AQ
11/09DICERNA PHARMACEUTICALS INC : Results of Operations and Financial Condition (form 8-K)
AQ
11/09Dicerna Announces Third Quarter 2021 Financial Results and Provides a Business Update
BU
11/05Dicerna Presents PHYOX2 and Primary Hyperoxaluria Healthcare Utilization Data at Americ..
AQ
11/04áDicerna Presents PHYOX™2 and Primary Hyperoxaluria Healthcare Utilization Data a..
BU
11/02Dicerna to Report Third Quarter 2021 Financial Results on Nov. 9, 2021
BU
10/20DICERNA PHARMACEUTICALS : Announces Results for PHYOX4, Single-Dose Study of Nedosiran in ..
AQ
10/19DICERNA PHARMACEUTICALS : Announces Results for PHYOX™4, Single-Dose Study of Nedosi..
BU
10/15DICERNA PHARMACEUTICALS : Announces Data to Be Presented at American Society of Nephrology..
BU
10/14DICERNA PHARMACEUTICALS : Announces Poster Presentations at American Association for the S..
BU
10/12DICERNA PHARMACEUTICALS : Corporate Overview
PU
10/01DICERNA PHARMACEUTICALS : Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
09/29DICERNA PHARMACEUTICALS : Initiates Phase 1 Clinical Trial of DCR-AUD, a Novel Investigati..
AQ
09/28DICERNA PHARMACEUTICALS : Initiates Phase 1 Clinical Trial of DCR-AUD, a Novel Investigati..
BU
09/22DICERNA PHARMACEUTICALS : Announces New Executive Leadership Appointments
BU
09/07DICERNA PHARMACEUTICALS : Corporate Overview
PU
09/02DICERNA PHARMACEUTICALS : to Participate in 16th Annual Citi Biopharma Conference
BU
08/12DICERNA PHARMACEUTICALS : Corporate Overview
PU
08/09DICERNA PHARMACEUTICALS : Q2 Earnings Snapshot
AQ
08/09DICERNA PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND ..
AQ
08/09DICERNA PHARMACEUTICALS INC : Results of Operations and Financial Condition (form 8-K)
AQ
08/09DICERNA PHARMACEUTICALS : Announces Second Quarter 2021 Financial Results and Provides a B..
BU
08/06DICERNA PHARMACEUTICALS INC : Regulation FD Disclosure (form 8-K)
AQ
08/05DICERNA PHARMACEUTICALS : Reports Positive Top-Line Results From PHYOX™2 Pivotal Cli..
BU
08/02DICERNA PHARMACEUTICALS : to Report Second Quarter 2021 Financial Results on Aug. 9, 2021
BU
07/30DICERNA PHARMACEUTICALS : Announces FDA Clearance of Investigational New Drug Application ..
AQ
07/29DICERNA PHARMACEUTICALS : Announces FDA Clearance of Investigational New Drug (IND) Applic..
BU
07/23DICERNA PHARMACEUTICALS : Corporate Overview
PU
07/21DICERNA PHARMACEUTICALS : Announces Interim Results From Phase 1 Trial of Belcesiran for T..
BU
07/08DICERNA PHARMACEUTICALS : Corporate Overview
PU
07/02DICERNA PHARMACEUTICALS : Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
07/01DICERNA PHARMACEUTICALS : Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
06/22DICERNA PHARMACEUTICALS : Initiates Patient Dosing in ESTRELLA Phase 2 Clinical Trial of B..
BU
06/17DICERNA PHARMACEUTICALS : Announces Dosing Completion in Nedosiran PHYOX4 Clinical Trial f..
AQ
06/16DICERNA PHARMACEUTICALS : Announces Dosing Completion in Nedosiran PHYOX™4 Clinical ..
BU
06/04DICERNA PHARMACEUTICALS INC : Submission of Matters to a Vote of Security Holders (form 8-..
AQ
06/03DICERNA PHARMACEUTICALS : to Participate in 42nd Annual Goldman Sachs Global Healthcare Co..
BU
06/01DICERNA PHARMACEUTICALS : Corporate Overview
PU
05/28DICERNA PHARMACEUTICALS : Announces FDA Acceptance of Lilly's Investigational New Drug (IN..
AQ
05/27DICERNA PHARMACEUTICALS : Corporate Overview
PU
05/27DICERNA PHARMACEUTICALS : Announces FDA Acceptance of Lilly's Investigational New Drug (IN..
BU
05/24DICERNA PHARMACEUTICALS : Announces Boehringer Ingelheim's Acceptance of Candidate for Dev..
BU
05/12DICERNA PHARMACEUTICALS : to Participate in Upcoming Investor Conferences
BU
05/12DICERNA PHARMACEUTICALS : Corporate Overview
PU
05/07DICERNA PHARMACEUTICALS : Earned $25 Million Milestone Payment in Connection With Roche's ..
PU
05/06DICERNA PHARMACEUTICALS : Q1 Earnings Snapshot
AQ
05/06DICERNA PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND ..
AQ
05/06DICERNA PHARMACEUTICALS : Announces First Quarter 2021 Financial Results and Provides a Bu..
BU
04/27OLIGONUCLEOTIDES : Chemistry & Therapeutics Symposium
PU
04/12DICERNA PHARMACEUTICALS INC : Entry into a Material Definitive Agreement (form 8-K)
AQ
04/09ROYALTY PHARMA : Acquires Oxlumo Royalty Interest from Dicerna for Up to $240 Million
AQ
04/09DICERNA PHARMACEUTICALS : Sells OXLUMO (lumasiran) Royalty Interest to Royalty Pharma for ..
AQ
04/02DICERNA PHARMACEUTICALS : Corporate Overview
PU
04/01DICERNA PHARMACEUTICALS : Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
03/30DICERNA PHARMACEUTICALS : GalXC-Plus™ RNAi Technology Delivers Target Knockdown Acro..
BU
03/25DICERNA PHARMACEUTICALS : to Present New GalXC-Plus Nonclinical CNS Data at Oligonucleotid..
AQ
03/24DICERNA PHARMACEUTICALS : to Present New GalXC-Plus™ Nonclinical CNS Data at Oligonu..
BU
03/12DICERNA PHARMACEUTICALS INC : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Y..
AQ
03/11DICERNA PHARMACEUTICALS : Corporate Overview
PU
03/11DICERNA PHARMACEUTICALS : to Host Webinar on DCR-AUD Alcohol Use Disorder Candidate on Mar..
BU
03/04DICERNA PHARMACEUTICALS : Announces Roche's Initiation of GalXC™ RNAi Candidate RG63..
BU
03/02DICERNA PHARMACEUTICALS : Corporate Overview
PU
03/02DICERNA PHARMACEUTICALS INC : Regulation FD Disclosure (form 8-K)
AQ
02/26DICERNA PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND ..
AQ
1  2  3  4  5  6Next
Upcoming event on DICERNA PHARMACEUTICALS, INC.